Tremor News and Research

Latest Tremor News and Research

PD risk factors for potential clinical screening identified

A meta-analysis has identified 19 risk factors that significantly impact a person’s risk for Parkinson’s disease and could be of potential value for clinical screening, say the authors.

20 Aug 2012

FDA approves InSightec's ExAblate Neuro system clinical trial for tremor dominant Parkinson's Disease

InSightec Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS), announced that it has received approval from the US Food and Drug Administration to begin a Phase I clinical trial evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor dominant Parkinson's Disease.

20 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

Surprise result in caffeine trial for Parkinson’s patients

Caffeine treatment may improve motor symptoms in patients with Parkinson’s disease, research suggests.

7 Aug 2012

Scientists link some cases of Essential Tremor to specific genetic problem

Researchers at the University of Montreal and its affiliated CHU Sainte-Justine and CHUM hospitals have linked some cases of Essential Tremor (ET) to a specific genetic problem. ET is the most common movement disorder, becoming increasingly frequent with increasing age, which is characterized by an involuntary shaking movement (tremor) that occurs with motion, particularly when doing precise fine movement.

3 Aug 2012

Parkinson’s disease treatment: an interview with Ted Dawson

Parkinson’s disease is a disorder which usually affects people in their 60’s and older. It is caused by the loss of dopamine neurons in the brain leading to rigidity, slowness of movement, tremor, problems with balance and so forth.

31 Jul 2012

DBS achieves stable motor improvements in Parkinson’s

Deep brain stimulation for patients with Parkinson’s disease achieves improvements in motor symptoms that are sustained over 3 years, report researchers.

19 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Novel way to monitor real-time chemical changes in brains of patients undergoing DBS

Mayo Clinic researchers have found a novel way to monitor real-time chemical changes in the brains of patients undergoing deep brain stimulation (DBS). The groundbreaking insight will help physicians more effectively use DBS to treat brain disorders such as Parkinson's disease, depression and Tourette syndrome.

16 Jul 2012

Botulinum toxin may help prevent arm tremor in people with MS

Botulinum toxin may help prevent shaking or tremor in the arms and hands of people with multiple sclerosis (MS), according to new research published in the July 3, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 Jul 2012

Sitagliptin appears to reduce severity of reactive hypoglycemia

The diabetes drug sitagliptin appears to reduce the severity of reactive hypoglycemia, a form of low blood sugar that occurs after a meal, a preliminary study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Deep brain stimulation reduces binge eating

Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

18 Jun 2012

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.

14 Jun 2012

Potential predictor of fast PD progression identified

The identification of genetic variants of the α-synuclein gene may help to predict which individuals with idiopathic Parkinson’s disease are likely to experience fast progression of motor symptoms, according to findings from a US-based genetic study.

14 Jun 2012

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Great Lakes NeuroTechnologies announced today that the U.S. Patent Office has issued claims under patent number 8,187,209 covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

6 Jun 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Colonic tissue may help predict Parkinson's disease

Two studies by neurological researchers at Rush University Medical Center suggest that, in the future, colonic tissue obtained during either colonoscopy or flexible sigmoidoscopy may be used to predict who will develop Parkinson's disease, a neurodegenerative disorder of aging that that leads to progressive deterioration of motor function due to loss of neurons in the brain that produce dopamine, a neurotransmitter essential to executing movement.

16 May 2012

UVA achieves two important milestones in VISIUS Surgical Theatre

IMRIS Inc. today reported on the preliminary successes that the University of Virginia (UVA) has achieved in their VISIUS Surgical Theatre. UVA clinicians have treated over 50 patients in their VISIUS Surgical Theatre since its opening, achieving two important milestones in the use of their new intraoperative imaging capabilities.

9 May 2012

Conference to focus on deep brain stimulation for OCD, depression

Deep brain stimulation, increasingly recognized as an effective therapy for certain cases of Parkinson's disease, dystonia and tremor, also may help patients who suffer from obsessive-compulsive disorder or depression that fails to respond to other treatments.

27 Apr 2012